Industry finds flaws Indian per-capita income-linked price approach for patented drugs
This article was originally published in Scrip
An Indian government panel's suggestion to set prices of patented medicines using a per capita income-linked reference pricing model has sparked criticism from several quarters of the pharmaceutical industry, which believes that the approach is flawed and that a suitable access model should be considered instead.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.